Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 12, 2025Frontiers in OncologyOpen Access

Editorial: The role of adjuvant and neoadjuvant therapy in resectable esophageal cancer

View Full Paper
Ask AI
Bookmark
Share

Authors

XLXiaokun LiZCZhuang‐Zhuang CongYQYong Qiang

Discussion

Loading...

Member takes

Overview

Editorial reviews neoadjuvant therapy and survival improvements in locally advanced esophageal cancer patients, indicating significant benefits from combined treatments.

Key Points

  • Neoadjuvant therapy significantly improves survival rates in locally advanced esophageal cancer patients, enhancing treatment efficacy.
  • In a recent trial, patients receiving neoadjuvant chemoradiotherapy showed a 13% absolute survival benefit over surgery alone at 10 years.
  • The study utilized randomized controlled trial methods to compare the outcomes of different neoadjuvant treatment regimens in resectable cases.
  • Individualizing treatment approaches remains essential to further enhance outcomes for patients with locally advanced esophageal squamous cell carcinoma.

Cite This Study

Li et al. (2025) studied this question.

synapsesocial.com/papers/68d41d9b713b0b5dfea66786https://doi.org/10.3389/fonc.2025.1688480
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Analysis of the safety and efficacy of PD-1/PD-L1 inhibitors combined with chemotherapy in the treatment of locally advanced resectable esophageal squamous cell carcinoma: a systematic review and meta-analysis based on four randomized controlled trials2025
  2. 2Preoperative radiotherapy in patients with locally advanced esophageal squamous cell carcinoma: a narrative review2025
  3. 3474. NEOADJUVANT CHEMOIMMUNOTHERAPY VERSUS CHEMOTHERAPY PLUS ESOPHAGECTOMY FOR ESOPHAGEAL SQUAMOUS CELL CARCINOMA: PRIMARY RESULT OF A RANDOMIZED CLINICAL TRIAL2025
  4. 4236. SAFETY AND EFFICACY OF CAMRELIZUMAB COMBINED WITH RADIOTHERAPY AS NEOADJUVANT THERAPY FOR LOCALLY ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA2025
  5. 5Research Progress on Neoadjuvant Immunotherapy in Esophageal Squamous Cell Carcinoma2025